Stocks
Karuna Therapeutics, Inc.KRTX
NASDAQHealthcareBiotechnology$329.83+0.03%
Focused on developing novel therapies for psychiatric and neurological conditions, this biopharmaceutical company gained investor attention after positive clinical trial results for its lead schizophrenia treatment. The firm's pipeline targets underserved CNS disorders, with potential blockbuster candidates driving its premium valuation.
Market Cap: $12.6B52W Range: $158.38 – $329.99
Congressional Interest in Karuna Therapeutics, Inc. (KRTX)
1 member of Congress has disclosed 1 trade in Karuna Therapeutics, Inc. (KRTX), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading KRTX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-04-10 | Daniel Goldman | sell | $1K – $15K |